Convergence Investment Partners LLC Invests $303,000 in Natera, Inc. (NASDAQ:NTRA)

Convergence Investment Partners LLC bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 2,796 shares of the medical research company’s stock, valued at approximately $303,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in NTRA. International Assets Investment Management LLC lifted its holdings in Natera by 6,007.5% in the fourth quarter. International Assets Investment Management LLC now owns 7,329 shares of the medical research company’s stock valued at $459,000 after acquiring an additional 7,209 shares during the period. CWM LLC boosted its holdings in Natera by 41.8% during the fourth quarter. CWM LLC now owns 1,867 shares of the medical research company’s stock worth $117,000 after buying an additional 550 shares in the last quarter. Russell Investments Group Ltd. grew its position in Natera by 378.0% during the fourth quarter. Russell Investments Group Ltd. now owns 64,679 shares of the medical research company’s stock valued at $4,051,000 after buying an additional 51,147 shares during the period. Victory Capital Management Inc. grew its position in Natera by 13.9% during the fourth quarter. Victory Capital Management Inc. now owns 26,109 shares of the medical research company’s stock valued at $1,635,000 after buying an additional 3,178 shares during the period. Finally, First Horizon Advisors Inc. increased its holdings in Natera by 36.1% in the fourth quarter. First Horizon Advisors Inc. now owns 2,089 shares of the medical research company’s stock valued at $131,000 after buying an additional 554 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Natera

In other news, insider Daniel Rabinowitz sold 1,057 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $102.77, for a total value of $108,627.89. Following the transaction, the insider now owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Steven Leonard Chapman sold 6,105 shares of the stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $111.61, for a total transaction of $681,379.05. Following the completion of the transaction, the chief executive officer now owns 213,351 shares of the company’s stock, valued at approximately $23,812,105.11. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Rabinowitz sold 1,057 shares of Natera stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $102.77, for a total transaction of $108,627.89. Following the completion of the sale, the insider now owns 206,400 shares of the company’s stock, valued at approximately $21,211,728. The disclosure for this sale can be found here. Insiders sold 92,388 shares of company stock worth $10,205,064 in the last 90 days. Insiders own 7.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on NTRA shares. Stephens reissued an “overweight” rating and set a $125.00 target price on shares of Natera in a research note on Friday, August 9th. UBS Group cut their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Robert W. Baird upped their target price on Natera from $117.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, August 9th. Piper Sandler upped their price objective on shares of Natera from $120.00 to $150.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 13th. Finally, TD Cowen upped their price target on shares of Natera from $137.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $120.07.

Natera Price Performance

NASDAQ:NTRA opened at $118.26 on Tuesday. Natera, Inc. has a one year low of $36.90 and a one year high of $124.83. The stock has a market cap of $14.52 billion, a PE ratio of -37.90 and a beta of 1.48. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The stock has a 50 day moving average price of $111.25 and a 200 day moving average price of $101.20.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same quarter in the previous year, the firm earned ($0.97) EPS. The company’s quarterly revenue was up 58.1% compared to the same quarter last year. Equities research analysts expect that Natera, Inc. will post -2.03 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.